The trial assessed the safety and efficacy of nalbuphine ER for treating chronic cough in idiopathic pulmonary fibrosis. Credit: Towfiqu barbhuiya on Unsplash.

Trevi Therapeutics has reported positive data from the Phase II CANAL clinical trial of its investigational therapy, Haduvio (oral nalbuphine extended-release (ER)), to treat chronic cough in idiopathic pulmonary fibrosis (IPF).

Carried out in the UK, the two-treatment, randomised, double-blind, placebo-controlled, two-period crossover trial assessed the safety and efficacy of nalbuphine ER.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Assessing the impact of nalbuphine ER tablets on the mean daytime cough frequency at day 22 versus placebo as evaluated by an objective cough monitor was the trial’s primary efficacy endpoint.

According to findings, treatment with Haduvio offered a statistically significant 52.5% change versus placebo on the primary endpoint.

Additionally, the therapy led to a 75.1% decline in the geometric mean percent change in daytime cough frequency.

The crucial secondary endpoints on the subject- and clinician-reported outcomes were also found to be statistically significant.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The safety data of Haduvio from the trial was in line with already reported ones from prior studies. 

Trevi Therapeutics president and CEO Jennifer Good said: “We are pleased to announce the positive results from the full set of subjects from the CANAL trial, which are consistent with the previously announced interim analysis and further demonstrated that Haduvio has the potential to reduce IPF patients’ cough.

“We analysed the change of 24hr cough frequency as well as daytime cough frequency and observed consistent reductions for both measurements.

“There are no approved therapies for chronic cough in these patients, and we are excited to continue our development in this indication and look forward to starting our next clinical trial for these patients in the first half of 2023.”

In March this year, the company completed subject enrolment in the CANAL trial.